Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Plasmodium falciparum DNA damage-inducible protein 1 (PfDdi1) is an essential retropepsin (A2 family aspartic protease) that serves as a critical component of the parasite's ubiquitin-proteasome system (UPS) and unfolded protein response (UPR) (Onchieku et al., 2021; Arora et al., 2023). It functions as a proteasome shuttle protein, facilitating the degradation of polyubiquitinated substrates and the repair of DNA-protein crosslinks (DPCs) (Arora et al., 2023; Oduro-Kwatenga et al., 2025). PfDdi1 is indispensable for the survival and development of the malaria parasite across its life cycle stages (Arora et al., 2023). Recent research has identified PfDdi1 as a primary target of artemisinin and its derivatives, which inhibit its proteolytic activity and lead to the toxic accumulation of damaged proteins and DNA (Onchieku et al., 2021; Oduro-Kwatenga et al., 2025). The inhibition of PfDdi1 results in the accumulation of toxic protein aggregates and unrepaired DNA damage, which are lethal to the parasite (Onchieku et al., 2021). Furthermore, its retroviral-like protease (RVP) domain makes it a potential target for HIV protease inhibitors like lopinavir, offering a novel avenue for antimalarial drug development and combination therapies to combat drug-resistant malaria (Arora et al., 2023; UniProt Q8IM03). This target is particularly attractive due to its essentiality and the presence of a unique protease fold that may allow for selective inhibition over human homologs (Onchieku et al., 2021).
Inhibition of PfDdi1 protease activity leads to the accumulation of polyubiquitinated proteins and DNA-protein crosslinks, causing cellular toxicity and parasite death.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Plasmodium falciparum DNA damage-inducible protein 1 (PfDdi1).